Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 04:27 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Penny Stock Picks » Strong Buy: IGXT (Mcap $31 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013

Thread Tools Search this Thread
Old 12-30-2012, 08:57 PM   Nav to Top  #1
Senior Trader
Biohero's Avatar
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 111
Reputation: 36
Biohero is on a distinguished road
Default IGXT (Mcap $31 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013

This is a real once in a lifetime opportuniy .GLTA

Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by mid 2013 because of its very low burn-rate of only $1.2 Mil a year !

2x New NDA filings for Migraine and Erectile Dysfunction indication in early 2013 . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .

IGXT has NO DEBT and current Market cap of only $29 M is really a BIG BIG BARGAIN .

My Target is $8-12 within 2 Years .GLTA

Intelgenx (IGXT.OB)

Market Cap : $ 31 M
Cash: $ 3 M
Burn-rate : only $1.2 M a year

Price : $0.63
Shares Out : 50 M ( 26 M shares are held by Insiders + Institutions)

From latest Earnings :
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "In addition, following the positive pivotal bioequivalence results announced last quarter for our anti-migraine VersaFilm product, we are pleased to confirm that a recent pre-NDA meeting with FDA confirmed that we remain on track to file our 505(b)(2) NDA submission in the first quarter of 2013. This product, along with our Par project, is our top pipeline priority for the immediate future."

Prodcut Pipeline

Latest Presentation Oct 2012

Big Buying by Institutions

Analyst Coverage:

IGXT gets 18 month $3.00 Price Target from AEGIS CAPITAL CORP on October 5th, 2012

The Event- Forfivo XL is now officially launched in the US

IntelGenx striving to create a second Biovail
Biohero is offline   Rate this post Yes | No Reply With Quote

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: IGXT (Mcap $29 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013 Biohero US Penny Stock Picks 0 12-27-2012 08:34 AM
Strong Buy: SUPN = 2x MEGA DRUGS APPROVED // 1x BLOCKBUSTER IN P3 // LOW FLOAT 5 M = 500%++ POTEN Biohero US Stock Picks 0 12-03-2012 09:50 AM
Strong Buy: (IGXT)Mcap 28 M// Partnership THIS MONTH/1x Approved drug Biohero US Penny Stock Picks 0 01-26-2012 08:55 AM
Strong Buy: IGXT - FDA approval in 3Q (Mcap 31 M$) 10 Drugs in Pipeline !!! biotechmaster US Penny Stock Picks 20 11-11-2011 07:48 AM
Strong Buy: Viagra Spray-NDA in 4Q11 (Mcap 5 M)= 10 BAGGER biotechmaster US Penny Stock Picks 2 04-07-2011 01:50 AM

Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On